PMID- 31158876
OWN - NLM
STAT- MEDLINE
DCOM- 20200213
LR  - 20210318
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 170
IP  - 11
DP  - 2019 Jun 4
TI  - Would You Recommend Prostate-Specific Antigen Screening for This Patient?: Grand 
      Rounds Discussion From Beth Israel Deaconess Medical Center.
PG  - 770-778
LID - 10.7326/M19-1072 [doi]
AB  - Prostate cancer is the third most common cancer type in the United States 
      overall, accounting for 9.5% of new cancer cases and 5% of cancer deaths. The 
      goal of prostate-specific antigen (PSA)-based screening is to identify 
      early-stage disease that can be treated successfully. The U.S. Preventive 
      Services Task Force (USPSTF) reviewed evidence on the benefits and harms of 
      PSA-based screening and treatment of screen-detected prostate cancer. It found 
      that PSA-based screening in men aged 55 to 69 years prevents approximately 1.3 
      deaths from prostate cancer over 13 years per 1000 men screened and 3 cases of 
      metastatic cancer per 1000 men screened, with no reduction in all-cause 
      mortality. No benefit was found for PSA-based screening in men aged 70 years and 
      older. On the basis of its review, the USPSTF concluded that the decision for men 
      aged 55 to 69 years to have PSA-based screening should be an individual one and 
      should include a discussion of the potential benefits and harms. Here, 2 
      experts-an internist and a urologist-discuss the key points of a shared 
      decision-making conversation about PSA-based prostate cancer screening, the 
      PSA-based screening strategy that optimizes benefit and minimizes harm, and the 
      PSA threshold at which they would recommend further diagnostic testing.
FAU - Burns, Risa B
AU  - Burns RB
AD  - Beth Israel Deaconess Medical Center, Boston, Massachusetts (R.B.B., A.F.O., 
      G.W.S.).
FAU - Olumi, Aria F
AU  - Olumi AF
AD  - Beth Israel Deaconess Medical Center, Boston, Massachusetts (R.B.B., A.F.O., 
      G.W.S.).
FAU - Owens, Douglas K
AU  - Owens DK
AD  - VA Palo Alto Health Care System, Palo Alto, California, and Stanford University, 
      Stanford, California (D.K.O.).
FAU - Smetana, Gerald W
AU  - Smetana GW
AD  - Beth Israel Deaconess Medical Center, Boston, Massachusetts (R.B.B., A.F.O., 
      G.W.S.).
LA  - eng
PT  - Clinical Conference
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Aged
MH  - Decision Making, Shared
MH  - *Early Detection of Cancer
MH  - Humans
MH  - Internal Medicine
MH  - Male
MH  - Practice Guidelines as Topic
MH  - Prostate-Specific Antigen/*blood
MH  - Prostatic Neoplasms/*diagnosis
MH  - Referral and Consultation
MH  - Risk Assessment
MH  - Teaching Rounds
MH  - Urology
EDAT- 2019/06/04 06:00
MHDA- 2020/02/14 06:00
CRDT- 2019/06/04 06:00
PHST- 2019/06/04 06:00 [entrez]
PHST- 2019/06/04 06:00 [pubmed]
PHST- 2020/02/14 06:00 [medline]
AID - 2735233 [pii]
AID - 10.7326/M19-1072 [doi]
PST - ppublish
SO  - Ann Intern Med. 2019 Jun 4;170(11):770-778. doi: 10.7326/M19-1072.